Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Dividends payables (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Dividends payables for 3 consecutive years, with $35389.0 as the latest value for Q4 2025.

  • On a quarterly basis, Dividends payables fell 99.05% to $35389.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $35389.0, a 99.05% decrease, with the full-year FY2025 number at $1577.0, down 99.97% from a year prior.
  • Dividends payables was $35389.0 for Q4 2025 at PharmaCyte Biotech, up from $1577.0 in the prior quarter.
  • In the past five years, Dividends payables ranged from a high of $6.3 million in Q2 2024 to a low of $1577.0 in Q2 2025.
  • A 3-year average of $3.4 million and a median of $3.9 million in 2023 define the central range for Dividends payables.
  • Peak YoY movement for Dividends payables: soared 1849.31% in 2024, then crashed 99.97% in 2025.
  • PharmaCyte Biotech's Dividends payables stood at $4.1 million in 2023, then fell by 9.15% to $3.7 million in 2024, then tumbled by 99.05% to $35389.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Dividends payables are $35389.0 (Q4 2025), $1577.0 (Q2 2025), and $3.7 million (Q4 2024).